The Impact of Smoking Cessation on Hospitalization and Psychiatric Medication Utilization among People with Serious Mental Illness

被引:3
|
作者
Kertes, Jennifer [1 ]
Reisner, Orit Stein [2 ]
Grunhaus, Leon [3 ]
Neumark, Yehuda [4 ,5 ]
机构
[1] Maccabi HealthCare, Dept Hlth Evaluat & Res, Jerusalem, Israel
[2] Maccabi HealthCare Serv, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Braun Hebrew Univ, Hadassah Sch Publ Hlth & Community Med, Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Hadassah Braun Sch Publ Hlth & Community Med, POB 12272, IL-9112102 Jerusalem, Israel
关键词
Smoking cessation; serious mental illness; hospitalization; medication utilization; defined daily dose; psychotropic medications; BIPOLAR DISORDER; LIFE EXPECTANCY; SCHIZOPHRENIA; MORTALITY; SMOKERS; PREDICTORS; EFFICACY; SAFETY; IMPLEMENTATION; ASSOCIATION;
D O I
10.1080/10826084.2021.1942057
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Despite the high prevalence of smoking amongst people with serious mental illness (SMI), referral rates to smoking cessation programs (SCPs) are low. Mental health workers reticence to refer to SCPs has been attributed, in part, to their belief that quitting will have a deleterious effect on their patients' mental health status. Objectives: This study's objective was to determine if participating in a smoking cessation program had an adverse effect on mental health status among people with SMI, measured here by a change in hospitalization occurrence or psychiatric medication utilization. People with SMI who had participated in at least one SCP session in a large health maintenance organization (n = 403) were compared to an age-gender-diagnosis matched sample of SMI smokers (1,209) who had never participated. Results: No change in psychiatric hospitalization occurrence pre- versus post-SCP participation was found among participants (Pre:7.2% vs. Post:5.2, p = 0.2) or nonparticipants (Pre:7.0% vs. Post:6.0%, p = 0.2). Mean defined daily dose (DDD) for anti-psychotic, mood stabilizer, anti-depressant and anxiolytic medications also did not change over time for participants and nonparticipants. However, participants who did not complete the SCP and didn't quit had a 0.35 higher mean DDD for anti-psychotic medications compared with participants who had completed the SCP or quit, and with nonparticipants (p = 0.006), and were the only group to exhibit an increase in mean antipsychotic DDD over time (Pre:1.42, Post:1.63). SCP participation was not associated with hospitalization occurrence or psychiatric medication utilization. Conclusions/Importance: Smoking cessation should be encouraged, with close monitoring during the quit process.
引用
收藏
页码:1543 / 1550
页数:8
相关论文
共 50 条
  • [21] The Whole Package: A Multi-Component Smoking Cessation Intervention for Adults With Serious Mental Illness: A Qualitative Study
    Leutwyler, Heather
    Hubbard, Erin
    Humfleet, Gary
    Souza, Richard
    Balestra, Dennys
    Wallhagen, Margaret
    TOBACCO USE INSIGHTS, 2024, 17
  • [22] User-Centered Design of Learn to Quit, a Smoking Cessation Smartphone App for People With Serious Mental Illness
    Vilardaga, Roger
    Rizo, Javier
    Zeng, Emily
    Kientz, Julie A.
    Ries, Richard
    Otis, Chad
    Hernandez, Kayla
    JMIR SERIOUS GAMES, 2018, 6 (01):
  • [23] A Pilot Randomized Controlled Trial of a Multicomponent Smoking Cessation Intervention for Adults with Serious Mental Illness
    Leutwyler, Heather
    Hubbard, Erin
    Bussell, Theo
    Balestra, Dennys
    Cooper, Bruce
    Souza, Richard B.
    Humfleet, Gary
    GAMES FOR HEALTH JOURNAL, 2024,
  • [24] Psychiatric genetic counseling for serious mental illness: Impact on psychopathology and psychotropic medication adherence
    Morris, Emily
    Batallones, Rolan
    Ryan, Jane
    Slomp, Caitlin
    Carrion, Prescilla
    Albert, Arianne
    Austin, Jehannine
    PSYCHIATRY RESEARCH, 2021, 296
  • [25] History and Correlates of Smoking Cessation Behaviors Among Smokers With Serious Mental Illness
    Lubitz, Su Fen
    Flitter, Alex
    Wileyto, E. Paul
    Ziedonis, Douglas
    Stevens, Nathaniel
    Leone, Frank
    Mandell, David
    Kimberly, John
    Beidas, Rinad
    Schnoll, Robert A.
    NICOTINE & TOBACCO RESEARCH, 2020, 22 (09) : 1492 - 1499
  • [26] Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis
    Roberts, Emmert
    Evins, A. Eden
    McNeill, Ann
    Robson, Debbie
    ADDICTION, 2016, 111 (04) : 599 - 612
  • [27] Preferences for Smoking Cessation Support from Family and Friends Among Adults with Serious Mental Illness
    Aschbrenner, Kelly A.
    Naslund, John A.
    Gill, Lydia
    Bartels, Stephen J.
    O'Malley, A. James
    Brunette, Mary F.
    PSYCHIATRIC QUARTERLY, 2017, 88 (04) : 701 - 710
  • [28] The Impact of Psychiatric Symptoms on Condom Self-Efficacy Among People With Serious Mental Illness
    Pinho, Veronica
    McKinnon, Karen
    Cournos, Francine
    Pala, Andrea Norcini
    Zea, Maria Cecilia
    Le, Huynh-Nhu
    Mattos, Paulo E.
    Pinto, Diana
    Mann, Claudio Gruber
    Wainberg, Milton L.
    PSYCHIATRIC REHABILITATION JOURNAL, 2020, 43 (03) : 205 - 213
  • [29] Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
    Mazereel, Victor
    Detraux, Johan
    Vancampfort, Davy
    van Winkel, Ruud
    De Hert, Marc
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [30] The Acceptability and Effectiveness of Videos Promoting Smoking Cessation Among Australians Experiencing Mental Illness
    Sharma-Kumar, Ratika
    Puljevic, Cheneal
    Morphett, Kylie
    Meurk, Carla
    Gartner, Coral
    HEALTH EDUCATION & BEHAVIOR, 2022, 49 (03) : 506 - 515